Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.55 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.55 |
| ▸ | ROCK1 | Q13464 | 8/20 | 0.47 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.44 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.42 |
| ▸ | OGA | O60502 | 1/20 | 0.39 |
| ▸ | CDC7 | O00311 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18691293 | 0.88 | HRH3 (0.60) | HRH3HRH4ROCK1MAP4K4OGA | |
| SCHEMBL17626880 | 0.88 | HRH3 (0.60) | HRH3HRH4ROCK1MAP4K4OGA | |
| SCHEMBL17626627 | 0.88 | HRH3 (0.60) | HRH3HRH4ROCK1MAP4K4OGA | |
| SCHEMBL17626635 | 0.81 | HRH3 (0.60) | HRH3HRH4ROCK1CDC7CDK2 | |
| SCHEMBL15260161 | 0.81 | PDE10A (0.44) | HRH4PDE10AMAP4K4OGA | |
| SCHEMBL13018663 | 0.80 | HRH3 (0.70) | HRH3HRH4ROCK1CDC7CDK2 | |
| SCHEMBL31227206 | 0.78 | HRH3 (0.58) | HRH3HRH4ROCK1CDC7CDK2 | |
| SCHEMBL27730153 | 0.78 | HRH3 (0.58) | HRH3HRH4ROCK1CDC7CDK2 | |
| SCHEMBL17626690 | 0.78 | HRH3 (0.63) | HRH3HRH4ROCK1CDC7CDK2 | |
| SCHEMBL3536631 | 0.77 | HRH3 (0.55) | HRH3HRH4ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9801961-B2 | 2-phenylimidazo[1,2-a]pyrimidines as imaging agents | HOFFMANN-LA ROCHE INC. (US) | 2017-10-31 | — | — | US | disclosed |
| US-20170128598-A1 | 2-PHENYLIMIDAZO[1,2-A]PYRIMIDINES AS IMAGING AGENTS | HOFFMANN-LA ROCHE INC. (US) | 2017-05-11 | — | — | US | disclosed |
| EP-2999701-B1 | 2-PHENYLIMIDAZO[1,2-A]PYRIMIDINES AS IMAGING AGENTS | HOFFMANN LA ROCHE (US) | 2017-04-12 | — | — | EP | disclosed |
| EP-2999701-A1 | 2-PHENYLIMIDAZO[1,2-A]PYRIMIDINES AS IMAGING AGENTS | Hoffmann-La Roche Inc. (US) | 2016-03-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170128598-A1 | 2-PHENYLIMIDAZO[1,2-A]PYRIMIDINES AS IMAGING AGENTS | MAPT, AOC2, AOC3 | HRH3 14/4885HRH4 73/4885ROCK1 2550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.